# Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

> **NCT01252355** · PHASE3 · TERMINATED · sponsor: **Sanofi** · enrollment: 534 (actual)

## Conditions studied

- Multiple Sclerosis Relapse

## Interventions

- **DRUG:** Teriflunomide
- **DRUG:** Placebo (for teriflunomide)
- **DRUG:** Interferon-beta (IFN-beta)

## Key facts

- **NCT ID:** NCT01252355
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 534 (ACTUAL)
- **Why stopped:** Sponsor decision to prematurely stop the study, not linked to any safety concern.
- **Last updated:** 2014-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01252355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01252355, "Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01252355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*